F-1/A: Cuprina Holdings Eyes Nasdaq Listing with $15.9 Million IPO, Resale Offering Planned

Cuprina Holdings, a Singapore-based biomedical firm, is set to launch its initial public offering (IPO) aiming to raise $15.9 million while also facilitating a resale of shares by existing stakeholders.

Summary

• Cuprina Holdings, a biomedical company based in Singapore, has filed an amendment to its Form F-1 registration statement with the SEC.
• The company is planning an initial public offering (IPO) of 3,750,000 Class A Ordinary Shares.
• The anticipated IPO price is between $4.00 and $4.50 per share, with an assumed price of $4.25.
• Cuprina Holdings has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR.
• The closing of the IPO is contingent upon Nasdaq's approval of the listing application.
• Existing shareholders, Ms. Dorea Quek En Qi and Mr. Bryan Teo Ying Jie, are offering 1,500,000 Class A Ordinary Shares for resale.
• The company will not receive any proceeds from the resale of shares by the existing shareholders.
• Immediately after the offering, there will be 3,915,000 Class A Ordinary Shares and 14,085,000 Class B Ordinary Shares issued and outstanding.
• Class B Ordinary Shares have 10 votes per share and are convertible into Class A Ordinary Shares.
• Cuprina Holdings will be a controlled company post-IPO, exempting it from certain corporate governance rules.
• The company is an emerging growth company and a foreign private issuer, entitling it to reduced reporting requirements.
• For the years ended December 31, 2021, 2022 and 2023, the company's revenue amounted to S$58,504, S$56,599 and S$100,773 (US$76,424), respectively, while it recorded net loss of S$519,686, S$1,094,516 and S$1,119,555 (US$849,048), respectively, for the same years.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has growth plans and operates in a promising sector, it also faces significant financial challenges and risks. The sentiment is neutral, reflecting both opportunities and uncertainties.

Positives

• The company has strategic plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China in the second half of 2024 and 2025.
• The company has attained ISO 13485:2016 standards for its manufacturing facility in Singapore.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance for its chronic wound care products.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.
• The company's independent registered public accounting firm expressed substantial doubt regarding its ability to continue as a going concern.

Risks

• The company's business and future growth prospects rely on industry development and consumer demand for its products.
• The company's revenue growth for a particular period is difficult to predict.
• The company may not be able to develop new products that are competitive or successful in the markets it has entered or plans to enter.
• The development and sale of certain of the company's pipeline products are heavily dependent on certain agreements with R&D partners.
• The company may be found to infringe on or violate the intellectual property rights of others.
• The company is subject to various governmental regulations relating to the labeling, marketing and sale of its products.
• The company is dependent on its key management and skilled personnel for its continued success and growth.
• The company is exposed to foreign exchange risks.
• The company is exposed to risks associated with joint ventures or strategic alliances.
• Adverse conditions in the global financial markets and the general economy may adversely affect the company's business, results of operations, financial position and prospects.
• The company is dependent on a few of its major customers and suppliers.
• The reduction or discontinuation of government grants currently available to the company may have a material adverse effect on its business operations and financial condition.
• The company's historical growth and performance may not be indicative of its future growth and performance.
• The company's Class A Ordinary Shares could be subject to significant price volatility should its earnings fail to meet the expectations of investors.
• As a part of its business strategy, the company plans to expand its business operations into new geographic markets including mainland China and Hong Kong, which could subject it to rules, regulations and influence of regulators in those jurisdictions.
• The company will be a controlled company within the meaning of the rules of Nasdaq and, as a result, will rely on exemptions from certain corporate governance requirements that provide protection to shareholders of other companies.
• It may be difficult for you to enforce any judgment obtained in the United States against us, our directors, executive officers or our affiliates.
• The ability of our subsidiary in Singapore to distribute dividends to us may be subject to restrictions under applicable laws.
• It is not certain if we will be classified as a Singapore tax resident.
• Any adverse material changes to the Singapore market (whether localized or resulting from economic or other conditions) such as the occurrence of an economic recession, pandemic or widespread outbreak of an infectious disease (such as COVID-19), could have a material adverse effect on our business, results of operations and financial condition.
• An active trading market for our Class A Ordinary Shares may not be established or, if established, may not continue and the trading price for our Class A Ordinary Shares may fluctuate significantly.
• The offering price of the primary offering and resale offering could differ.
• We may not maintain the listing of our Class A Ordinary Shares on the Nasdaq which could limit investors ability to make transactions in Class A Ordinary Shares and subject us to additional trading restrictions.
• The trading price of our Class A Ordinary Shares may be volatile, which could result in substantial losses to investors.
• If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our Class A Ordinary Shares, the market price for our Class A Ordinary Shares and trading volume could decline.
• Our corporate actions are significantly influenced by our directors, officers and principal shareholders, who have the ability to exert significant influence over important corporate matters that require approval of shareholders while their interests may differ from those of the other shareholders.
• The dual-class structure of our ordinary shares may adversely affect the trading market for our Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of our Class A Ordinary Shares could adversely affect their market price.
• Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our Class A Ordinary Shares for a return on your investment.
• Certain recent initial public offerings of companies with public floats comparable to our anticipated public float have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility, which may make it difficult for prospective investors to assess the value of our Ordinary Shares
• Because our public offering price per Class A Ordinary Shares is substantially higher than our net tangible book value per Class A Ordinary Shares, you will experience immediate and substantial dilution.
• You must rely on the judgment of our management as to the uses of the net proceeds from this offering, and such uses may not produce income or increase our share price.
• If we are classified as a passive foreign investment company, United States taxpayers who own our securities may have adverse United States federal income tax consequences.
• We may need additional capital, and we may be unable to obtain such capital in a timely manner or on acceptable terms, or at all.
• We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements.
• We are a foreign private issuer within the meaning of the Exchange Act, and as such we are exempt from certain provisions applicable to United States domestic public companies.
• As a company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards.
• We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses to us.
• We will incur significantly increased costs and devote substantial management time as a result of the listing of our Class A Ordinary Shares on the Nasdaq.
• You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law.
• If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud and our business may be harmed and our stock price may be adversely impacted.
• Certain judgments obtained against us by our shareholders may not be enforceable.

Future Outlook

The company intends to use the net proceeds from the offering for growth and expansion into new markets, research and development activities, building brand awareness, investment in equipment and infrastructure, and loan repayment.

Industry Context

The company operates in the biomedical and biotechnology industry, focusing on chronic wound care and cosmeceuticals. The chronic wound care market is expected to grow due to an aging population and increasing prevalence of comorbidities like diabetes and obesity.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors in terms of financial performance.
• The document mentions that the company's products compete with those from larger, more established companies like Smith & Nephew and ConvaTec.
• The document highlights the company's focus on cost-effectiveness and value proposition compared to competing options.

Related Party Transactions

• The document discloses various related party transactions, including amounts due to and from related parties for working capital purposes and share subscriptions.

Stakeholder Impact

• Shareholders will be subject to potential dilution and market volatility.
• Employees may benefit from the company's growth and expansion plans.
• Customers may benefit from the company's development of new and innovative products.

Next Steps

• Obtain Nasdaq approval for listing.
• Complete the initial public offering.
• Expand into new geographic markets.
• Continue research and development activities.
• Strengthen brand awareness.

Key Dates

Keywords

IPO, initial public offering, Cuprina Holdings, biomedical, Nasdaq, Class A Ordinary Shares, resale offering, wound care, medical devices, Singapore